Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Are you Dr. Ajani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jaffer Ajani, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is a Professor of Medicine at University Tex Houston.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1980 - 1982
Tulane UniversityResidency, Internal Medicine, 1977 - 1980
UPMC Medical Education/Altoona HospitalResidency, Family Medicine, 1975 - 1977- UPMC Medical Education/Altoona HospitalInternship, Transitional Year, 1974 - 1975
Indira Gandhi Medical CollegeClass of 1971
Certifications & Licensure
FL State Medical License 2021 - Present
AZ State Medical License 2024 - 2026
WA State Medical License 2024 - 2026
AL State Medical License 2024 - 2025
GA State Medical License 2024 - 2025
LA State Medical License 1977 - 2025- LA State Medical License 2024 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.Taroh Satoh, Philippe Barthélémy, Lucia Nogova, Kazunori Honda, Hidekazu Hirano
European Journal of Cancer. 2025-03-11 - Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma.Jane E Rogers, Michael Leung, Jaffer A Ajani
Expert Opinion on Drug Metabolism & Toxicology. 2025-03-04 - Contemporary management of advanced gastric and gastroesophageal adenocarcinomas.Jane E Rogers, Jaffer A Ajani
Expert Review of Anticancer Therapy. 2025-02-08
Press Mentions
New Insights into Biology, Origin of Deadly Stomach and Esophageal CancersOctober 27th, 2022- Immunotherapy Is Now the First Choice for Esophageal CancerMay 31st, 2022
- BMS’ Opdivo Gets Late-Stage Oesophageal Cancer Nod from FDAMay 29th, 2022
- Join now to see all
Grant Support
- Common Stem Cell of Origin for Junctional and Gastric AdenocarcinomaUNIVERSITY OF HOUSTON2022–2027
